Genexine said Thursday that it has signed an agreement with National OncoVenture to jointly develop GX-188E, the company’s cervical cancer immunotherapy vaccine candidate.
GX-188E is an immunotherapy vaccine that treats cervical cancer caused by HPV 16 or 18 infection. The company had received approval from the Ministry of Food and Drug Safety to conduct a phase 1b/2 clinical trial for a combination treatment of GX-188E and an approved immune checkpoint inhibitor.
During the project, the National OncoVenture plans to complete initial phase 2 clinical trials and confirm the safety and efficacy of the treatment on cervical cancer patients, who do not have any alternative form of therapy, along with Genexine.
Genexine has already conducted a phase 2 clinical trial for GX-188E in patients with cervical intraepithelial neoplasia (CIN) in Korea and has confirmed the safety of GX-188E. The company has also found that the drug eliminates and effectively induces a lesion-specific anti-cancer immune response.
“GX-188E not only has excellent therapeutic efficacy in cervical cancer but also the possibility of treating other various carcinomas,” a company official said. “The study, which is being conducted jointly with a national government agency, will help to overcome the limitations of anticancer immunotherapy by confirming the synergy between immunosuppressant and immunotherapy vaccine.”
<© Korea Biomedical Review, All rights reserved.>